{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T22:43:11Z","timestamp":1722379391206},"reference-count":17,"publisher":"Japanese Circulation Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2019,1,25]]},"DOI":"10.1253\/circj.cj-18-1355","type":"journal-article","created":{"date-parts":[[2018,12,28]],"date-time":"2018-12-28T22:28:48Z","timestamp":1546036128000},"page":"283-284","source":"Crossref","is-referenced-by-count":1,"title":["Unexpected, But Reasonable Association Between Anderson-Fabry Disease and Coronary Vasospasm"],"prefix":"10.1253","volume":"83","author":[{"given":"Tetsuya","family":"Matoba","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kyushu University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Nakano","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kyushu University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Tsutsui","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kyushu University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Zarate YA, Hopkin RJ. Fabry\u2019s disease. <i>Lancet<\/i> 2008; 372: 1427\u20131435.","DOI":"10.1016\/S0140-6736(08)61589-5"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Schiffmann R. Fabry disease. <i>Pharmacol Ther<\/i> 2009; 122: 65\u201377.","DOI":"10.1016\/j.pharmthera.2009.01.003"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Chimenti C, Morgante E, Tanzilli G, Mangieri E, Critelli G, Gaudio C, et al. Angina in Fabry disease reflects coronary small vessel disease. <i>Circ Heart Fail<\/i> 2008; 1: 161\u2013169.","DOI":"10.1161\/CIRCHEARTFAILURE.108.769729"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Kitani Y, Nakagawa N, Sakamoto N, Takeuchi T, Takahashi F, Momosaki K, et al. Unexpectedly high prevalence of coronary spastic angina in patients with Anderson-Fabry disease. <i>Circ J<\/i> 2019; 83: 481\u2013484.","DOI":"10.1253\/circj.CJ-18-0734"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. JCS Joint Working Group. Guidelines for diagnosis and treatment of patients with vasospastic angina (Coronary Spastic Angina) (JCS 2013): Digest version. <i>Circ J<\/i> 2014; 78: 2779\u20132801.","DOI":"10.1253\/circj.CJ-66-0098"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Matoba T, Shimokawa H. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in animals and humans. <i>J Pharmacol Sci<\/i> 2003; 92: 1\u20136.","DOI":"10.1254\/jphs.92.1"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Moore DF, Scott LT, Gladwin MT, Altarescu G, Kaneski C, Suzuki K, et al. Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: Reversal by enzyme replacement therapy. <i>Circulation<\/i> 2001; 104: 1506\u20131512.","DOI":"10.1161\/hc3801.096352"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Shen JS, Meng XL, Moore DF, Quirk JM, Shayman JA, Schiffmann R, et al. Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. <i>Mol Genet Metab<\/i> 2008; 95: 163\u2013168.","DOI":"10.1016\/j.ymgme.2008.06.016"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Katsuta H, Tsuboi K, Yamamoto H, Goto H. Correlations between serum cholesterol and vascular lesions in Fabry disease patients. <i>Circ J<\/i> 2018; 82: 3058\u20133063.","DOI":"10.1253\/circj.CJ-18-0378"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Choi S, Kim JA, Na HY, Cho SE, Park S, Jung SC, et al. Globotriaosylceramide induces lysosomal degradation of endothelial KCa3.1 in Fabry disease. <i>Arterioscler Thromb Vasc Biol<\/i> 2014; 34: 81\u201389.","DOI":"10.1161\/ATVBAHA.113.302200"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Satoh K. Globotriaosylceramide induces endothelial dysfunction in Fabry disease. <i>Arterioscler Thromb Vasc Biol<\/i> 2014; 34: 2\u20134.","DOI":"10.1161\/ATVBAHA.113.302744"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kandabashi T, Shimokawa H, Mukai Y, Matoba T, Kunihiro I, Morikawa K, et al. Involvement of rho-kinase in agonists-induced contractions of arteriosclerotic human arteries. <i>Arterioscler Thromb Vasc Biol<\/i> 2002; 22: 243\u2013248.","DOI":"10.1161\/hq0202.104274"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Ravarotto V, Carraro G, Pagnin E, Bertoldi G, Simioni F, Maiolino G, et al. Oxidative stress and the altered reaction to it in Fabry disease: A possible target for cardiovascular-renal remodeling? <i>PLoS One<\/i> 2018; 13: e0204618.","DOI":"10.1371\/journal.pone.0204618"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Liu PY, Liu YW, Lin LJ, Chen JH, Liao JK. Evidence for statin pleiotropy in humans: Differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. <i>Circulation<\/i> 2009; 119: 131\u2013138.","DOI":"10.1161\/CIRCULATIONAHA.108.813311"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Hiroi Y, Noma K, Kim HH, Sladojevic N, Tabit CE, Li Y, et al. Neuroprotection mediated by upregulation of endothelial nitric oxide synthase in Rho-associated, coiled-coil-containing kinase 2 deficient mice. <i>Circ J<\/i> 2018; 82: 1195\u20131204.","DOI":"10.1253\/circj.CJ-17-0732"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, Collins AB, et al. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. <i>Kidney Int<\/i> 2002; 62: 1933\u20131946.","DOI":"10.1046\/j.1523-1755.2002.00675.x"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Moore DF, Altarescu G, Herscovitch P, Schiffmann R. Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease. <i>BMC Neurol<\/i> 2002; 2: 4.","DOI":"10.1186\/1471-2377-2-4"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/83\/2\/83_CJ-18-1355\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T06:46:12Z","timestamp":1573627572000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/83\/2\/83_CJ-18-1355\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,25]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-18-1355","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,25]]}}}